{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T05:26:00Z","timestamp":1768713960427,"version":"3.49.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003968","name":"Iran National Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.pbb.2014.06.020","type":"journal-article","created":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T20:52:04Z","timestamp":1404247924000},"page":"297-304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Evaluation of the association between blood homocysteine concentration and the degree of behavioral symptoms in the 6-hydroxydopamine-induced Parkinsonism in rat"],"prefix":"10.1016","volume":"124","author":[{"given":"Hashem","family":"Haghdoost-Yazdi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Sarookhani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayda","family":"Faraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Negin","family":"Fraidouni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tahereh","family":"Dargahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Hosein","family":"Yaghoubidoust","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan","family":"Azhdari-Zarmehri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pbb.2014.06.020_bb0005","first-page":"527","article-title":"Sulfate and cysteine levels in the plasma of patients with Parkinson's disease","volume":"16","author":"Allain","year":"1995","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.pbb.2014.06.020_bb0010","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1515\/CCLM.2001.120","article-title":"Homocysteine in cerebrovascular disease: an independent risk factor for subcortical vascular encephalopathy","volume":"39","author":"Bertsch","year":"2001","journal-title":"Clin Chem Lab Med"},{"issue":"12","key":"10.1016\/j.pbb.2014.06.020_bb0015","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/81834","article-title":"Chronic systemic pesticide exposure reproduces features of Parkinson's disease","volume":"3","author":"Betarbet","year":"2000","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.pbb.2014.06.020_bb0020","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0301-0082(01)00003-X","article-title":"Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease","volume":"65","author":"Blum","year":"2001","journal-title":"Prog Neurobiol"},{"issue":"10","key":"10.1016\/j.pbb.2014.06.020_bb0025","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1021\/jm00232a007","article-title":"Catechol O-methyltransferase 9. Mechanism of inactivation by 6-hydroxydopamine","volume":"19","author":"Borchardt","year":"1976","journal-title":"J Med Chem"},{"key":"10.1016\/j.pbb.2014.06.020_bb0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10545-006-0106-5","article-title":"Homocysteine metabolism, hyperhomocysteinaemia and vascular disease: an overview","volume":"29","author":"Castro","year":"2006","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"10.1016\/j.pbb.2014.06.020_bb0035","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0896-6273(03)00568-3","article-title":"Parkinson's disease: mechanisms and models","volume":"39","author":"Dauer","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.pbb.2014.06.020_bb0040","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1124\/pr.54.4.599","article-title":"Homocysteine determinants and the evidence to what extent homocysteine determinants the risk of coronary heart disease","volume":"54","author":"de Bree","year":"2002","journal-title":"Pharmacol Rev"},{"issue":"6","key":"10.1016\/j.pbb.2014.06.020_bb0045","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1001\/archneur.1997.00550180070015","article-title":"Dietary antioxidants and Parkinson disease. The Rotterdam Study","volume":"54","author":"de Rijk","year":"1997","journal-title":"Arch Neurol"},{"key":"10.1016\/j.pbb.2014.06.020_bb0050","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1001\/archneur.57.10.1422","article-title":"Homocysteine and neurologic disease","volume":"57","author":"Diaz-Arrastia","year":"2000","journal-title":"Arch Neurol"},{"issue":"2","key":"10.1016\/j.pbb.2014.06.020_bb0055","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11011-009-9139-4","article-title":"Evidence that folic acid deficiency is a major determinant of hyperhomocysteinemia in Parkinson's disease","volume":"24","author":"dos Santos","year":"2009","journal-title":"Metab Brain Dis"},{"key":"10.1016\/j.pbb.2014.06.020_bb0060","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1046\/j.0022-3042.2001.00676.x","article-title":"Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease","volume":"80","author":"Duan","year":"2002","journal-title":"J Neurochem"},{"key":"10.1016\/j.pbb.2014.06.020_bb0065","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1385-299X(96)00015-3","article-title":"Basic neural transplantation techniques. I. Dissociated cell suspension grafts of embryonic ventral mesencephalon in the adult rat brain","volume":"1","author":"Dunnett","year":"1997","journal-title":"Brain Res Brain Res Protoc"},{"key":"10.1016\/j.pbb.2014.06.020_bb0070","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0169-328X(96)00018-6","article-title":"Expression of dopamine transporter mRNA and its binding site in fetal nigral cells transplanted into the striatum of 6-OHDA lesioned rat","volume":"39","author":"Fujita","year":"1996","journal-title":"Mol Brain Res"},{"key":"10.1016\/j.pbb.2014.06.020_bb0075","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1161\/01.STR.26.7.1166","article-title":"Serum folate and risk for ischemic stroke. First National Health and Nutrition Examination Survey epidemiologic follow-up study","volume":"26","author":"Giles","year":"1995","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.pbb.2014.06.020_bb0080","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.bbr.2012.05.011","article-title":"High intake of folic acid or complex of B vitamins provides anti-Parkinsonism effect: no role for serum level of homocysteine","volume":"233","author":"Haghdoost-Yazdi","year":"2012","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.pbb.2014.06.020_bb0085","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1001\/archneur.64.4.576","article-title":"Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease","volume":"64","author":"Hancock","year":"2007","journal-title":"Arch Neurol"},{"issue":"2","key":"10.1016\/j.pbb.2014.06.020_bb0090","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0091-3057(80)90353-6","article-title":"Circling behavior in rats with partial, unilateral nigro-striatal lesions: effect of amphetamine, apomorphine, and DOPA","volume":"12","author":"Hefti","year":"1980","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.pbb.2014.06.020_bb0095","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/ajcn\/73.3.613","article-title":"Determinants of plasma total homocysteine in the Framingham Offspring cohort","volume":"73","author":"Jacques","year":"2001","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.pbb.2014.06.020_bb0100","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1212\/WNL.47.6_Suppl_3.161S","article-title":"Oxidative stress and the pathogenesis of Parkinson's disease","volume":"47","author":"Jenner","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.pbb.2014.06.020_bb0105","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.neurobiolaging.2008.05.031","article-title":"Synergistic anti-Parkinsonism activity of high doses of B vitamins in a chronic cellular model","volume":"31","author":"Jia","year":"2010","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.pbb.2014.06.020_bb0110","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000007984","article-title":"Elevated plasma levels of homocysteine in Parkinson's disease","volume":"40","author":"Kuhn","year":"1998","journal-title":"Eur Neurol"},{"key":"10.1016\/j.pbb.2014.06.020_bb0115","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1046\/j.1471-4159.1995.64041703.x","article-title":"Free radical-generated neurotoxicity of 6-hydroxydopamine","volume":"64","author":"Kumar","year":"1995","journal-title":"J Neurochem"},{"issue":"1","key":"10.1016\/j.pbb.2014.06.020_bb0120","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/mds.20261","article-title":"Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients","volume":"20","author":"Lamberti","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.pbb.2014.06.020_bb0125","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/ana.20509","article-title":"Methylenetetrahydrofolate reductase C677T genotype and PD","volume":"57","author":"Lau","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pbb.2014.06.020_bb0130","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1016\/j.lfs.2004.12.011","article-title":"Physiological variation in plasma total homocysteine concentrations in rats","volume":"76","author":"Martins","year":"2005","journal-title":"Life Sci"},{"issue":"1","key":"10.1016\/j.pbb.2014.06.020_bb0135","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00002826-199702000-00007","article-title":"Effect of L-Dopa and the catechol-O-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats","volume":"20","author":"Miller","year":"1997","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.pbb.2014.06.020_bb0140","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3727\/096368909788341324","article-title":"Microtransplantation of dopaminergic cell suspensions: further characterization and optimization of grafting parameters","volume":"18","author":"Nikkhah","year":"2009","journal-title":"Cell Transplant"},{"key":"10.1016\/j.pbb.2014.06.020_bb0145","author":"Nutrient Requirements of Laboratory Animals","year":"1995"},{"key":"10.1016\/j.pbb.2014.06.020_bb0150","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/archneur.61.6.865","article-title":"Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations","volume":"61","author":"O'Suilleabhain","year":"2004","journal-title":"Arch Neurol"},{"key":"10.1016\/j.pbb.2014.06.020_bb0155","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1016\/j.febslet.2006.04.088","article-title":"Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia","volume":"580","author":"Obeid","year":"2006","journal-title":"FEBS Lett"},{"key":"10.1016\/j.pbb.2014.06.020_bb0160","series-title":"The rat brain in stereotaxic coordinates","author":"Paxinos","year":"2007"},{"key":"10.1016\/j.pbb.2014.06.020_bb0165","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1212\/01.WNL.0000032494.05619.93","article-title":"Homocysteine and cognitive function in the elderly: the Rotterdam Scan Study","volume":"59","author":"Prins","year":"2002","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.pbb.2014.06.020_bb0170","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/0306-4522(95)00066-R","article-title":"Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine","volume":"67","author":"Przedborski","year":"1995","journal-title":"Neuroscience"},{"key":"10.1016\/j.pbb.2014.06.020_bb0175","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1515\/CCLM.2005.191","article-title":"Homocysteine and B vitamins in mild cognitive impairment and dementia","volume":"43","author":"Quadri","year":"2005","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.pbb.2014.06.020_bb0180","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.neulet.2006.05.040","article-title":"Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease","volume":"404","author":"Religa","year":"2006","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pbb.2014.06.020_bb0185","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1006\/exnr.2000.7624","article-title":"Dopamine cell degeneration induced by intraventricular administration of 6-hydroxydopamine in the rat: similarities with cell loss","volume":"169","author":"Rodriquez","year":"2002","journal-title":"Exp Neurol"},{"key":"10.1016\/j.pbb.2014.06.020_bb0190","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/archneur.60.1.59","article-title":"Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease","volume":"60","author":"Rogers","year":"2003","journal-title":"Arch Neurol"},{"key":"10.1016\/j.pbb.2014.06.020_bb0195","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1212\/WNL.58.10.1539","article-title":"Relationship between plasma homocysteine levels and brain atrophy in healthy elderly individuals","volume":"58","author":"Sachdev","year":"2002","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.pbb.2014.06.020_bb0200","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S1734-1140(10)70386-8","article-title":"Effects of low doses of intracerebroventricular 6-OHDA on the levels of monoaminergic neurotransmitters in rat brain structures","volume":"62","author":"Sadakierska-Chudy","year":"2010","journal-title":"Pharmacol Rep"},{"issue":"2-3","key":"10.1016\/j.pbb.2014.06.020_bb0205","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0301-0082(96)00040-8","article-title":"The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments","volume":"50","author":"Schwarting","year":"1996","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.pbb.2014.06.020_bb0210","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1146\/annurev.nutr.19.1.217","article-title":"Homocysteine metabolism","volume":"19","author":"Selhub","year":"1999","journal-title":"Annu Rev Nutr"},{"key":"10.1016\/j.pbb.2014.06.020_bb0215","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/jn\/136.6.1726S","article-title":"The many facets if hiperhomocysteinemia: studies from the Framingham Cohorts","volume":"136","author":"Selhub","year":"2006","journal-title":"J Nutr"},{"key":"10.1016\/j.pbb.2014.06.020_bb0220","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1056\/NEJMoa011613","article-title":"Plasma homocysteine as a risk factor for dementia and Alzheimer's disease","volume":"346","author":"Seshadri","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pbb.2014.06.020_bb0225","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/10284150600583446","article-title":"Role of lifestyle factors on plasma homocysteine levels in Pakinson\u2019s disease patients treated with levodopa","volume":"9","author":"Siniscalchi","year":"2006","journal-title":"Nutr Neuosci"},{"issue":"5","key":"10.1016\/j.pbb.2014.06.020_bb0230","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.phrs.2005.05.013","article-title":"Increase in plasma homocysteine levels induced by drug treatments in neurologic patients","volume":"52","author":"Siniscalchi","year":"2005","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.pbb.2014.06.020_bb0235","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1046\/j.1471-4159.2000.0741605.x","article-title":"Autooxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease","volume":"77","author":"Soto-Otero","year":"2000","journal-title":"J Neurochem"},{"key":"10.1016\/j.pbb.2014.06.020_bb0240","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3389\/fphar.2012.00184","article-title":"Sequential loss of LC noradrenergic and dopaminergic neurons results in a correlation of dopaminergic neuronal number to striatal dopamine concentration","volume":"3","author":"Szot","year":"2012","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.pbb.2014.06.020_bb0245","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1006\/exnr.2000.7489","article-title":"Increased caspase 3 and bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease","volume":"166","author":"Tatton","year":"2000","journal-title":"Exp Neurol"},{"key":"10.1016\/j.pbb.2014.06.020_bb0250","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1176\/appi.ajp.159.12.2099","article-title":"Vitamin B12, folate, and homocysteine in depression: the Rotterdam Study","volume":"159","author":"Tiemeier","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pbb.2014.06.020_bb0255","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jns.2006.05.040","article-title":"Homocysteine serum levels and MTHFH C677T genotype in patients with Parkinson's disease, with and without levopoda therapy","volume":"248","author":"Todorovic","year":"2006","journal-title":"J Neurol Sci"},{"issue":"3","key":"10.1016\/j.pbb.2014.06.020_bb0260","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/0006-8993(70)90187-3","article-title":"Quantitative recording of rotational behavior in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system","volume":"24","author":"Ungerstedt","year":"1970","journal-title":"Brain Res"},{"issue":"1","key":"10.1016\/j.pbb.2014.06.020_bb0265","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S1007-4376(08)60003-9","article-title":"Effect and mechanism of homocysteine on Parkinson's disease induced by 6-OHDA","volume":"22","author":"Xing","year":"2008","journal-title":"J Nanjing Med Univ"},{"key":"10.1016\/j.pbb.2014.06.020_bb0270","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1212\/WNL.55.3.437","article-title":"Plasma homocysteine and MTHFR C677T genotype in levodopa treated patients with PD","volume":"55","author":"Yasui","year":"2000","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.pbb.2014.06.020_bb0275","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.parkreldis.2004.07.008","article-title":"Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications","volume":"11","author":"Zoccolella","year":"2005","journal-title":"Parkinsonism Relat Disord"}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305714001907?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305714001907?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:34:35Z","timestamp":1758774875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305714001907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":55,"alternative-id":["S0091305714001907"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2014.06.020","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the association between blood homocysteine concentration and the degree of behavioral symptoms in the 6-hydroxydopamine-induced Parkinsonism in rat","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2014.06.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}